The optimal timing to operate in patients with asymptomatic severe aortic stenosis (AS) remains controversial. Left ventricular global longitudinal strain (LV GLS) may help to identify patients who might benefit from undergoing earlier aortic valve replacement.
I n patients with asymptomatic severe aortic stenosis (AS), the current guidelines recommend a watchful waiting strategy until symptoms or left ventricular (LV) systolic dysfunction (ie, LV ejection fraction [LVEF]<50%) develop.
1,2
The optimal timing for intervention in these patients remains controversial. [3] [4] [5] [6] To determine whether the patients are truly asymptomatic, exercise testing is an important diagnostic tool. 7 However, in patients who are unable to perform this test, additional measurements are needed to better define the timing of the intervention. The assessment of LV systolic function by means of global longitudinal strain (GLS) by speckle tracking echocardiography has demonstrated that a significant proportion of patients with severe AS have impaired LV GLS despite having normal LVEF. [8] [9] [10] [11] [12] [13] Impaired LV GLS has been associated with worse outcomes in patients with symptomatic severe AS. 14 However, to our knowledge, the prevalence of impaired LV GLS among patients with asymptomatic severe AS and normal LVEF and the natural course and prognostic value of LV GLS in this subgroup of patients has not been extensively elucidated. Accordingly, this study aimed to investigate the prevalence of impaired LV GLS, as well as describing the natural course of serial changes in LV GLS and its prognostic implications, in asymptomatic patients with severe AS and preserved LVEF.
Methods

Study Population and Data Collection
From a multicenter international registry of patients with AS (Leiden University Medical Center, Heart Valve Clinic, and Institut Universitaire de Cardiologie et de Pneumologie de Québec), 220 patients with asymptomatic severe AS and preserved LV ejection fraction (LVEF > 50%) were selected and included in this retrospective study. Patients were selected based on available echocardiographic data at baseline (defined as the date of the first diagnosis of severe AS) with a feasible speckle tracking analysis. The definition of severe AS was based on an indexed aortic valve area (AVA) of less than 0.6 cm 2 /m 2 and/or a mean aortic valve gradient of 40 mm Hg or more and/or a peak aortic jet velocity of 4 m per second or more. 2, 15, 16 When available, the last transthoracic echocardiogram performed at the outpatient clinic or before aortic intervention was analyzed to evaluate the changes in valve hemodynamics, LV structure, and systolic function (including LV GLS). Measurements of the echocardiographic data were performed at each institution by experienced observers. Aortic valve intervention was defined as a surgical or transcatheter aortic valve replacement (AVR) or balloon valvuloplasty. The exclusion criteria were AS-related symptoms at baseline (eg, angina, syncope, or dyspnea), nonsevere AS, LVEF of less than 50%, having undergone prior aortic or mitral valve intervention, acute endocarditis at baseline, or the inability to measure LV GLS. In addition, an age-and sex-matched control group of 220 individuals without structural heart disease was included and used as a reference for measuring LV GLS. The transthoracic echocardiograms of this group of individuals were performed at the Leiden University Medical Center. The referral reasons to perform echocardiography in this group were atypical chest pain, palpitations, or syncope without the presence of a murmur.
Baseline patient demographics and clinical follow-up data were gathered and analyzed retrospectively using the departmental patient information systems and hospital records. This retrospective analysis of clinically acquired data was approved by the respective institutional review boards of each participating center, and consent was waived due to the retrospective nature of the study.
Transthoracic Echocardiography
Transthoracic echocardiography was performed in all patients at rest in the left decubitus position using commercially available ultrasonography systems. Conventional LV dimensions and function as well as AVA were measured following current recommendations. 17 Additionally, LV GLS
was measured with a 2-dimensional speckle tracking analysis on apical 2-, 3-, and 4-chamber views using commercially available software (Leiden University Medical Center: EchoPac, version 113; General Electric; Vingmed Ultrasound; Heart Valve Clinic Liège and Institut Universitaire de Cardiologie et de Pneumologie de Québec: 2D Cardiac Performance Analysis; TomTec Imaging Systems). 17 The frame rate of the 2-dimensional echocardiographic data was 40 frames per second or higher. Left ventricular GLS measures the shortening of the myocardial fibers in the longitudinal direction and is conventionally presented as a negative value. Therefore, a less negative LV GLS (ie, closer to 0) represents worse LV systolic function.
Clinical and Echocardiographic Follow-up and End Points
Patients were routinely followed up at the outpatient clinic according to guideline recommendations. 16 The onset of AS-related symptoms was recorded. The medical treatment and timing for AVR was left at the discretion of the treating physician of each institution. The time to symptom development and AVR, as well as the date of all-cause mortality, were recorded as clinical end points for assessing the prognosis.
Key Points
Question What is the natural course of left ventricular global longitudinal strain (LV GLS) and prevalence and prognostic value of impaired LV GLS in patients with asymptomatic severe aortic stenosis (AS) and preserved left ventricular ejection fraction?
Findings In this registry-based study of 220 patients, asymptomatic patients with severe AS showed significantly impaired LV GLS compared with 220 controls with further deterioration over time. Patients with impaired LV GLS at baseline showed a higher risk for developing symptoms and requiring aortic intervention.
Meaning Subclinical myocardial dysfunction that is characterized by impaired LV GLS is often present in patients with asymptomatic severe AS and is associated with symptom development and the need for intervention. these 2 groups were assessed using linear mixed models, with correction for age, sex, and time to follow-up. To further examine the prognostic value of LV GLS, the study population was divided according to the median baseline LV GLS value. Cumulative event rates were calculated with the Kaplan-Meier method. Two end points were defined: new onset of symptoms and AVR. Comparisons between the 2 groups were performed using log-rank tests. To assess the association between baseline LV GLS and the end points, Cox proportional hazards modeling was used. Spline models were fitted with overlaying confidence intervals for each end point vs LV GLS on the log-hazards scale, adjusting for age, sex, coronary artery disease, atrial Figure 1 and Figure 2 ), demonstrating increasing subclinical LV dysfunction over time.
Statistical Analysis
Of the 150 patients with echocardiographic follow-up and feasible speckle tracking analysis, 78 (52%) were symptomatic at follow-up echocardiography and 72 patients (48%) remained asymptomatic. The median (IQR) time from baseline to follow-up echocardiography was similar between these 2 groups (symptomatic, 13 [8-28] months vs asymptomatic, 12 [6-20] months; P = .09). Compared with asymptomatic patients, patients who developed symptoms at follow-up showed a higher prevalence of atrial fibrillation (22% vs 10%, respectively; P = .05) and had more frequent coronary artery disease (27% vs 16%, respectively; P = .09). Table 2 outlines the changes in valve hemodynamics and LV systolic function over time in these patients divided by symptom status at follow-up. Within both groups, the progression of AS was observed over time with a concomitant increase in LV mass index and impairment in LV GLS without changes in LVEF. Between both groups, no significant differences were observed in valve hemodynamics and LV systolic function, although LV mass index at follow-up was higher in patients with AS who developed symptoms. Example of a patient with asymptomatic severe aortic stenosis and preserved left ventricular (LV) ejection fraction (LVEF) at baseline (A) and at follow-up (B). Over time, the aortic stenosis severity and LV hypertrophy progressed and LV systolic function as assessed with LV global longitudinal strain (GLS) deteriorated, whereas LVEF remained unchanged. LVMI indicates left ventricular mass index.
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Prognostic Value of LV GLS in Symptom Development and AVR
Of the 220 patients with asymptomatic severe AS, 118 (54%) developed symptoms during a median follow-up of 12 months (IQR, (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . After a median follow-up period of 13 months (IQR, (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) To evaluate the prognostic value of baseline LV GLS, the study population was divided into 2 groups according to the median value of baseline LV GLS (more preserved, ≤−18.2% vs more impaired, >−18.2%) (eTable 2 in the Supplement). Compared with patients with more preserved LV GLS, patients with more impaired LV GLS had a higher prevalence of coronary artery disease (30% vs 15%, P = .01) and atrial fibrillation (26% vs 12%, P = .01). On transthoracic echocardiography, patients with more impaired LV GLS had a larger LV mass index and lower LVEF than patients with more preserved LV GLS, although mean LVEF was more than 60% in both groups (eTable 2 in the Supplement).
The cumulative event rates for developing symptoms were significantly higher in patients with a baseline LV GLS more than −18.2% compared with patients with an LV GLS −18.2% or less (59% vs 45% at 2-year follow-up, respectively, and 91% vs 79% at 5-year follow-up, respectively; log-rank P =. 02 ) ( Figure 3A) . Similarly, for AVR, the cumulative event rates were significantly higher in patients with impaired baseline LV GLS (>−18.2%) compared with patients with more preserved baseline LV GLS (≤−18.2%) after 2 years (66% vs 57%, respectively) and 5 years of follow-up (96% vs 82%, respectively; log-rank P = .03) ( Figure 3B ). The spline curves to assess the association between symptom development and aortic valve intervention across a range of LV GLS are shown in the eFigure in the Supplement. For both symptom development and aortic valve intervention, the linearity assumption was not violated (χ 2 ,0.83;P = .67, and χ 2 , 1.86; P = .41, respectively). For symptom development, a plateau can be seen (eFigure in the Supplement). For aortic valve intervention, a clear increase in hazard ratios can be observed for more impaired LV GLS (eFigure in the Supplement).
Discussion
This study demonstrated that in patients with asymptomatic severe AS and preserved LVEF, LV GLS assessed by speckle tracking imaging is impaired as compared with age-and sexmatched controls without structural heart disease. Over time, patients with asymptomatic severe AS showed a progression of AS severity accompanied by increasing LV hypertrophy and further impairment of LV GLS, while LVEF remained relatively unchanged. Patients with impaired LV GLS at baseline showed a higher risk for developing symptoms and for needing aortic valve intervention at follow-up as compared with patients with more preserved LV GLS. These findings suggest that LV GLS is a more sensitive marker for early myocardial damage than LVEF in this patient group and may help identify the patients who may benefit from earlier AVR.
LV GLS as a Marker for Subtle LV Dysfunction in Asymptomatic Severe AS
Symptom development and LV systolic dysfunction are the main factors that determine the timing of AVR in patients with severe AS.
1,2 However, decreased physical activity in the aging AS population may result in the underrecognition or late reporting of symptoms. 18 Zilberszac et al 19 demonstrated that 43% of elderly patients with asymptomatic severe AS who developed symptoms presented with severe heart failure symptoms (New York Heart Association class ≥III). The deterioration of LV systolic function defined by an LVEF of less than 50% can be regarded as a more objective parameter that indicates the need for AVR. However, this will only occur when the concentric remodeled left ventricle fails to maintain normal wall stress because of significant afterload mismatch. 20 At this stage, LV remodeling is characterized by progressive myocardial fibrosis, which is not reversible after an intervention. 21, 22 Therefore, more sensitive markers of LV systolic dysfunction are needed at an earlier stage to identify patients with severe AS who are at risk for irreversible myocardial damage. Recently, Stokke et al 12 showed that by inducing concentric LV remodeling with an increase in wall thickness and a reduction in diameter of the LV cavity, the LVEF can remain preserved, whereas LV GLS will be impaired. While the presence of impaired LV GLS with preserved LVEF has been described in symptomatic severe AS, ). Data demonstrating the prognostic effect of LV GLS in severe AS and its incremental value over these determinants are accumulating. In a cohort of 395 patients with AS, including 302 patients with severe AS, Kusunose et al 10 demonstrated that LV GLS was an independent predictor of allcause mortality and had incremental prognostic value on top of known echocardiographic predictors and symptom status. However, only 21% of these patients with severe AS were asymptomatic, and mortality rates were high (25%). Lancellotti et al 25 showed in 163 exclusively asymptomatic patients with severe AS that LV GLS was independently associated with the occurrence of cardiac events (ie, symptom development, eventual AVR, and death). Other studies have investigated the prognostic effect of LV GLS in asymptomatic AS, but these often had small patient samples, included moderate AS, or did not report symptom development as an end point. 6, [26] [27] [28] [29] In contrast, this study included a larger study population of 220 patients with asymptomatic severe AS with low mortality rates at follow-up (28 patients [13%]) and a more preserved LV GLS at baseline, thus representing a lower-risk study population in an earlier disease stage of severe AS. In addition, this study demonstrated that the natural course of LV GLS is characterized by further deterioration over time. These results provide further insights into the currently available literature by confirming that LV GLS is a sensitive marker for subclinical myocardial dysfunction and might aid in identifying patients who are at risk for symptom development and the need for intervention. Therefore, the present evaluation corroborates that LV GLS holds promise in the preoperative assessment of patients with asymptomatic severe AS without overt signs of LV dysfunction, although further prospective research is needed to determine the exact role of LV GLS in predicting AS progression and severity.
Clinical Implications
In patients with symptomatic severe AS, it has been demonstrated that myocardial fibrosis can be present and persist after AVR. 21 Diffuse myocardial fibrosis that was noninvasively assessed by native T1 mapping on cardiac magnetic resonance imaging was present in asymptomatic patients with severe AS and was associated with LV GLS that was measured by speckle tracking echocardiography. 36 This study shows that LV GLS is often impaired in asymptomatic severe AS and will further deteriorate if left untreated, while LVEF remains unchanged. This suggests that patients with impaired LV GLS at baseline have subclinical myocardial dysfunction that is )may help to define the optimal timing for AVR (before symptom development and irreversible myocardial damage occur).
Limitations
This study was limited by its retrospective design, which could have introduced a selection bias. Left ventricular GLS was measured using different platforms, which can lead to slight variations in the quantification of LV systolic dysfunction when considering the current variability in LV GLS measurements across vendors. Although intervendor differences in LV GLS measurements have been reported to be statistically significant, this bias was only moderate and the interobserver and intraobserver reproducibility of LV GLS were comparable with or superior to conventional echocardiographic parameters, such as LVEF. 38, 39 Furthermore, the precision of LV GLS has been shown to be high even in observers with low experience levels. 39 The differences in mean LV GLS values or in the prevalence of LV systolic dysfunction based on an LV GLS value of more impaired than −19.6% were not observed across the participating centers. Finally, as the participating centers are tertiary referral hospitals for AVR, referral bias could be present, with subsequent increased rates of AVR. The decision of referral for AVR was left to the discretion of the treating cardiologist.
Conclusions
In asymptomatic severe AS, most patients have impaired LV GLS at the initial diagnosis despite preserved LVEF. Furthermore, during follow-up and before intervention, a further deterioration of LV GLS occurred without a change in LVEF, whereas AS severity progressed and LV hypertrophy increased. Impaired LV GLS at baseline was associated with a higher risk of symptom development and need for aortic valve intervention. Therefore, assessing LV GLS holds promise in the risk assessment of asymptomatic severe AS, although further prospective studies in larger patient populations are warranted to establish the exact role of LV GLS, integrated with other markers of AS severity and progression, in identifying patients who might benefit from earlier aortic valve intervention. Log-rank test; P = .02
Kaplan-Meier estimates for event rates for symptom development (A) and intervention (B) in patients with asymptomatic aortic stenosis. Cumulative event rates were compared with the study population that was divided according to left ventricular global longitudinal strain (LV GLS) at baseline more than −18.2% (orange line indicates more impaired) vs −18.2% or less (blue line indicates more preserved).
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Original Investigation Research when to do the procedure. Yet even after determining that severe aortic stenosis (AS) is present (itself a controversial measurement, but not the subject of this commentary), the decision to operate is still based on the crude measurement (often done by eyeballing) of ejection fraction (EF) and that most subjective of assessments, symptoms.
2 Why are symptoms so problematic?
There can be errors on both ends of the spectrum. First, breathlessness is a part of daily living: if you do not get short of breath when you exercise, then you are not really exercising, making it challenging to determine the contribution of the AS. By contrast, some patients who are truly limited by AS curtail their activities to the point that they can honestly deny having symptoms. The unreliability of EF and symptoms has led to a search for alternative indices to determine the appropriate time for intervention. In this issue of JAMA Cardiology, Vollema et al 3 from
Leiden, the Netherlands, Liege, Belgium, and Quebec, Canada, combine experience to provide data on the utility of global longitudinal strain (GLS) to time intervention in 220 asymptomatic patients with severe AS. Global longitudinal strain, an echocardiographic measure of long-axis left ventricular shortening (and hence a negative number), has emerged in the past decade as a more reliable predictor of outcomes than EF in various clinical conditions from acute heart failure 4 to mitral regurgitation. 5 In this study, a comparison group of 220 age-and sex-matched controls (from Leiden) provided the normative GLS data against which to assess the patients. They found that the patients with AS had worse GLS (by convention, that means closer to 0) than the healthy controls (−17.9% vs −19.6%; P < .001), which further deteriorates over time, and those with more impaired GLS were more likely to progress to developing symptoms or AVR over a median follow-up period of 12 months (interquartile range, 7-23). It is tempting to make the connection that patients with asymptomatic AS with lower GLS should be considered for undergoing early intervention, but before coming to that conclusion, a few points should be considered. First, while many studies have shown an adverse association of low GLS with outcomes and mortality, 6 this one did not. Despite having more symptom development and AVRs, there is no evidence that the outcomes were adversely affected by low GLS (much less that a randomized clinical trial of GLS-guided earlier intervention would have led to better outcomes). Indeed, a median follow-up of 12 months is unlikely to detect differences in hard end points. It is also difficult to know which value of GLS should cause concern, as they had a generous definition for abnormality, being any value less than the median GLS in the controls (−19.6%) rather than outside the usual 95% limits of normal ( ෂ −15.5%). Furthermore, one of the end points is the aforementioned unclear concept of symptoms, which were not well defined, making interpretation challenging. Perhaps exercise echocardiography, which was popularized by these investigators, could have better defined the differences in functional capacity. There are also some technical issues that should be considered, as previously GLS that was calculated on different vendors' equipment yielded inconsistent results.
7 That this study could be implemented with 2 approaches (vendor-specific hardware and software in Leiden and vendor-neutral software elsewhere) with indistinguishable mean values among their respective cohorts is strong validation for the strain standardization effort that was organized by the European Association of Cardiovascular Imaging and the American Society of Echocardiography. After publishing a consensus document on strain methods, 8 the task force organized a clinical trial that showed mean GLS to be within 2% among 9 vendors. 9 Furthermore, GLS was shown to have better interobserver agreement than EF and lower vendor variability than traditional parameters, such as transmitral E velocity and posterior wall thickness. It is gratifying to see a multicenter Abbreviations: AVR, aortic valve replacement; LV, left ventricular.
